0001209191-18-047808.txt : 20180821
0001209191-18-047808.hdr.sgml : 20180821
20180821175208
ACCESSION NUMBER: 0001209191-18-047808
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170613
FILED AS OF DATE: 20180821
DATE AS OF CHANGE: 20180821
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: YORDON JEFFREY
CENTRAL INDEX KEY: 0001189013
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38112
FILM NUMBER: 181031063
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Athenex, Inc.
CENTRAL INDEX KEY: 0001300699
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 431985966
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1001 MAIN STREET
STREET 2: SUITE 600
CITY: BUFFALO
STATE: NY
ZIP: 14203
BUSINESS PHONE: 716-898-8625
MAIL ADDRESS:
STREET 1: 1001 MAIN STREET
STREET 2: SUITE 600
CITY: BUFFALO
STATE: NY
ZIP: 14203
FORMER COMPANY:
FORMER CONFORMED NAME: Kinex Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20131223
FORMER COMPANY:
FORMER CONFORMED NAME: Kinex Pharmaceuticals LLC
DATE OF NAME CHANGE: 20040817
4/A
1
doc4a.xml
FORM 4/A SUBMISSION
X0306
4/A
2017-06-13
2017-06-21
0
0001300699
Athenex, Inc.
ATNX
0001189013
YORDON JEFFREY
C/O ATHENEX, INC.
1001 MAIN STREET, SUITE 600
BUFFALO
NY
14203
0
1
0
0
See Remarks
Stock Option (Right to Buy)
11.00
2017-06-13
4
A
0
230000
0.00
A
2027-06-13
Common Stock
230000
230000
D
This option was previously reported by Mr. Yordon. This amendment is being filed to correct the transaction date, exercise date, and expiration date.
This option vests in three equal annual installments beginning on June 13, 2018.
Officer: Chief Operating Officer and President, Athenex Pharmaceutical Division
/s/ Teresa Bair, Attorney-in-Fact
2018-08-21